Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Metabolic effects of dialyzate glucose in chronic hemodialysis: Results from a prospective, randomized crossover trial
Nephrology Dialysis Transplantation, Volume 27, No. 4, Year 2012
Notification
URL copied to clipboard!
Description
Background. There is no agreement concerning dialyzate glucose concentration in hemodialysis (HD) and 100 and 200 mg/dL (G100 and G200) are frequently used. G200 may result in diffusive glucose flux into the patient, with consequent hyperglycemia and hyperinsulinism, and electrolyte alterations, in particular potassium (K) and phosphorus (P). This trial compared metabolic effects of G100 versus G200. Methods. Chronic HD patients participated in this randomized, single masked, controlled crossover trial (www.clinicaltrials.gov: NCT00618033) consisting of two consecutive 3-week segments with G100 and G200, respectively. Intradialytic serum glucose (SG) and insulin concentrations (SI) were measured at 0, 30, 60, 120, 180, 240 min and immediately post-HD; P and K were measured at 0, 120, 180 min and post-HD. Hypoglycemia was defined as an SG <70 mg/dL. Mean SG and SI were computed as area under the curve divided by treatment time. Results. Fourteen diabetic and 15 non-diabetic subjects were studied. SG was significantly higher with G200 as compared to G100, both in diabetic {G200: 192.8 ± 48.1 mg/dL; G100: 154.0 ± 27.3 mg/dL; difference 38.8 [95% confidence interval (CI): 21.2-56.4] mg/dL; P < 0.001} and non-diabetic subjects [G200: 127.0 ± 11.2 mg/dL; G100 106.5 ± 10.8 mg/dL; difference 20.6 (95% CI: 15.3-25.9) mg/dL; P < 0.001]. SI was significantly higher with G200 in non-diabetic subjects. Frequency of hypoglycemia, P and K serum levels, interdialytic weight gain and adverse intradialytic events did not differ significantly between G100 and G200. Conclusion. G200 may exert unfavorable metabolic effects in chronic HD patients, in particular hyperglycemia and hyperinsulinism, the latter in non-diabetic subjects. © 2011 The Author.
Authors & Co-Authors
Raimann, Jochen G.
United States, New York
Renal Research Institute, Llc
United States, New York
Beth Israel Medical Center
Kruse, Anja E.
United States, New York
Renal Research Institute, Llc
United States, New York
Beth Israel Medical Center
Switzerland, Bern
University Hospital Bern
Thijssen, Stephan
United States, New York
Renal Research Institute, Llc
United States, New York
Beth Israel Medical Center
Kuntsevich, Viktoriya I.
United States, New York
Beth Israel Medical Center
Dabel, Pascal
United States, New York
Beth Israel Medical Center
Bachar, Mostafa
Saudi Arabia, Riyadh
College of Sciences
Díaz-Buxó, José A.
United States, Waltham
Fresenius Medical Care North America
Levin, Nathan W.
United States, New York
Renal Research Institute, Llc
United States, New York
Beth Israel Medical Center
Kotanko, Peter
United States, New York
Renal Research Institute, Llc
United States, New York
Beth Israel Medical Center
Statistics
Citations: 28
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1093/ndt/gfr520
ISSN:
09310509
e-ISSN:
14602385
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Design
Cohort Study